Pharmaceuticals: data and challenges of the Swiss economy

Context

In a Nutshell

• Over 56,000 direct employees in the sector
• Exports of 100 billion Swiss francs in 2025
• Top R&D investments in the OECD

Key Facts

• What: Performance and data of the pharmaceutical industry
• When: Data collected between 2023 and 2025
• Where: Switzerland (international scene)
• Who: 350 active companies, including Novartis and Roche
• Amount: 100 billion Swiss francs in exports

The pharmaceutical industry confirms its role as a central driver for the Swiss economy, despite evolving international pressures. According to 2023 data from the Federal Statistical Office (FSO), the sector comprises around 350 companies operating in the country, the vast majority of which operate internationally. Alongside global giants under Swiss control such as Novartis, Roche, and Sandoz, there are numerous subsidiaries of foreign competitors like Pfizer, Takeda, and AstraZeneca.

Market Structure and Employment

Although global giants attract media attention, the sector's structure is diverse: nearly 6 out of 10 companies are classified as micro-enterprises, with fewer than 10 employees. However, the ability to generate employment is driven by large multinationals. The sector's workforce has grown by over 30,000 since the mid-1990s boom, reaching 56,000 people in 2023. The impact on the labor market extends beyond direct boundaries: according to a 2024 study by BAK Economics, the pharmaceutical value chain generates around 250,000 indirect jobs. This volume of jobs requires high skills, as 67% of the workforce holds a higher education diploma, a percentage well above the Swiss average of 45%. For those looking for work or evaluating their Swiss payslip, this sector represents one of the most qualifying and remuneratively solid professional outlets in the country.

Contribution to National Wealth

The contribution to economic growth is also measurable through added value. After a quarter-century of continuous expansion, the industry recorded a slight decline in 2022 and 2023 but remains the fourth most important economic sector in Switzerland, with a 6% share in national wealth creation, positioning itself right after wholesale trade, the real estate sector, and public employment. The economic influence extends to broader horizons: including indirect added value, estimated at 30 billion Swiss francs, BAK Economics calculates that the pharmaceutical industry generates almost one in ten Swiss francs. Vital sectors such as machine tools and construction directly benefit from investments produced by the pharmaceutical supply chain.

Operational details

The competitiveness of the sector is based on unparalleled innovative capacity but must contend with a rapidly changing geopolitical landscape. Data published in 2025 by the Swiss Federal Statistical Office (SFSO) highlights that the chemical-pharmaceutical industry is the absolute leader in research and development (R&D) investments in Switzerland. In 2023, investments reached nearly 5.5 billion francs, accounting for almost one-third of the total private sector R&D expenditure, which amounts to approximately 18 billion francs.

Leadership in Research and Development

In percentage terms, Switzerland stands out distinctly within the OECD landscape. While the average pharmaceutical R&D investment among developed countries that are members of the organization is 8%, Switzerland records significantly higher values, solidifying its position as a global hub for innovation. This research intensity is crucial for maintaining its competitive advantage, especially considering that chemical-pharmaceutical products, particularly serums and vaccines, constitute the second-largest category of goods exported from Switzerland, surpassed only by gold.

Export Performance and Global Risks

In 2025, foreign sales exceeded 100 billion francs, representing nearly 22% of the total value of Swiss exports. It is through these products that the country achieves the most substantial trade surpluses, amounting to approximately 35 billion francs in the last year. Despite these record numbers, Switzerland remains the second-largest exporter of pharmaceutical products worldwide, behind Germany but ahead of the United States. However, the source text warns of tangible risks: pressures from the United States and the rise of new countries in the development and production of medicines, particularly China, could threaten Switzerland's position on the international stage. This global competition directly impacts economic stability and the cost of living in Switzerland, as a decline in exports could affect the state budget and households' purchasing power.

Recommended tools

For an updated estimate, use the net salary calculator and the CHF-EUR exchange comparator.

Key points

To understand the country's economic future, it is essential to analyze not only current data but also the dynamics that will influence the sector in the coming years. The Swiss pharmaceutical industry stands at a crossroads: on one hand, a highly qualified workforce and massive investments in innovation; on the other hand, increasingly aggressive international competition.

Implications for the labor market

The demand for highly qualified personnel, with 67% of employees holding higher education degrees, clearly indicates the direction of the market. For workers, this means that access to this sector requires continuous training and advanced specializations. The stability of the 250,000 indirect jobs depends on the ability of large multinationals to maintain their leadership, which is in turn linked to research outcomes.

Future prospects and strategies

The challenges posed by the United States and emerging markets such as China should not be underestimated. Switzerland's ability to defend its global market share (currently second in the world) will depend on its capacity to sustain R&D investment rates above the OECD average. This high-tech and high-wage environment remains a pillar of the national economy, but it requires political and strategic vigilance from federal authorities to protect this "flagship."

To assess how the performance of this sector impacts disposable income and family financial planning, it is useful to utilize specific tools. If you work in this sector or are considering a career in the pharmaceutical industry, you can calculate your net salary and taxes.

Calculate your salary

Source: swissinfo.ch